Literature DB >> 18448867

Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice.

Katsuya Morita1, Naoyo Motoyama, Tomoya Kitayama, Norimitsu Morioka, Koki Kifune, Toshihiro Dohi.   

Abstract

Neuropathic pain is refractory against conventional analgesics, and thus novel medicaments are desired for the treatment. Glycinergic neurons are localized in specific brain regions, including the spinal cord, where they play an important role in the regulation of pain signal transduction. Glycine transporter (GlyT)1, present in glial cells, and GlyT2, located in neurons, play roles in modulating glycinergic neurotransmission by clearing synaptically released glycine or supplying glycine to the neurons and thus could modify pain signal transmission in the spinal cord. In this study, we demonstrated that i.v. or intrathecal administration of GlyT1 inhibitors, cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl methyl)amino methylcarboxylic acid (ORG25935) or sarcosine, and GlyT2 inhibitors, 4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocyclopently)-methyl]benzamide (ORG25543) and (O-[(2-benzyloxyphenyl-3-fluorophenyl)methyl]-L-serine) (ALX1393), or knockdown of spinal GlyTs by small interfering RNA of GlyTs mRNA produced a profound antiallodynia effect in a partial peripheral nerve ligation model and other neuropathic pain models in mice. The antiallodynia effect is mediated through spinal glycine receptor alpha3. These results established GlyTs as the target molecules for the development of medicaments for neuropathic pain. However, these manipulations to stimulate glycinergic neuronal activity were without effect during the 4 days after nerve injury, whereas manipulations to inhibit glycinergic neuronal activity protected against the development of allodynia in this phase. The results implied that the timing of medication with their inhibitors should be considered, because glycinergic control of pain was reversed in the critical period of 3 to 4 days after surgery. This may also provide important information for understanding the underlying molecular mechanisms of the development of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448867     DOI: 10.1124/jpet.108.136267

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

1.  Receptors: cannabis medicine without a high.

Authors:  Macdonald J Christie; Christopher W Vaughan
Journal:  Nat Chem Biol       Date:  2011-05       Impact factor: 15.040

Review 2.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

3.  Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-04       Impact factor: 5.045

Review 4.  Reviewing the case for compromised spinal inhibition in neuropathic pain.

Authors:  M A Gradwell; R J Callister; B A Graham
Journal:  J Neural Transm (Vienna)       Date:  2019-10-22       Impact factor: 3.575

5.  Characterization of the rapid transcriptional response to long-term sensitization training in Aplysia californica.

Authors:  Samantha Herdegen; Geraldine Holmes; Ashly Cyriac; Irina E Calin-Jageman; Robert J Calin-Jageman
Journal:  Neurobiol Learn Mem       Date:  2014-08-10       Impact factor: 2.877

6.  N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn.

Authors:  Hyo-Jin Jeong; Robert J Vandenberg; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

7.  Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor.

Authors:  Maria V Centeno; Amelia Mutso; Magali Millecamps; A Vania Apkarian
Journal:  Pain       Date:  2009-07-03       Impact factor: 6.961

8.  Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.

Authors:  A Mingorance-Le Meur; P Ghisdal; B Mullier; P De Ron; P Downey; C Van Der Perren; V Declercq; S Cornelis; M Famelart; J Van Asperen; E Jnoff; J P Courade
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

9.  Risk factors for vitamin D deficiency in sickle cell disease.

Authors:  Jin Han; Xu Zhang; Santosh L Saraf; Michel Gowhari; Robert E Molokie; Johara Hassan; Shivi Jain; Binal N Shah; Taimur Abbasi; Roberto F Machado; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

10.  Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport.

Authors:  Amelia R Edington; Audra A McKinzie; Aaron J Reynolds; Michael Kassiou; Renae M Ryan; Robert J Vandenberg
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.